Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.

Slides:

Advertisements

Similar presentations

Brown JR et al. Proc ASH 2013;Abstract 523.

Advertisements

Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)

Neue Perspektiven in der Therapie Follikulärer Lymphome.

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine.

Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously.

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,

Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain.

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,

Geisler C et al. Proc ASH 2011;Abstract 290.

MRD testing: which platforms, which patients?

Bloodstream Infections in Adult Patients Undergoing Cord Blood Transplantation from Unrelated Donors after Myeloablative Conditioning Regimen Jaime Sanz,

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,

WHAT IS THE BEST Front-Line REGIMEN for Patients With CLL

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup by Marie-Anne Hospital, Thomas Prebet,

Adaptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells Enhances Lymphocyte Recovery after Cyclophosphamide - Fludarabine.

Hepatitis C in the rituximab era

Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and.

Transplants for the elderly in myeloma

Goals of Therapy in Relapsed CLL

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia by Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin,

Ferrajoli A et al. Proc ASH 2010;Abstract 1395.

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk.

Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias by David Gómez-Almaguer, Manuel Solano-Genesta,

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML by Nona Shayegi, Michael Kramer,

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial by Peter Dreger,

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Patients’ priorities in selecting chronic lymphocytic leukemia treatments by Carol Mansfield, Anthony Masaquel, Jessie Sutphin, Elisa Weiss, Meghan Gutierrez,

by Michael F. Leahy, and J. Harvey Turner

Vitolo U et al. Proc ASH 2011;Abstract 777.

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

What is the optimal management of a 43-year-old man with high-risk FL not in CR after R-chemo? Answer: Radioimmunotherapy Peter Martin, M.D. The Charles,

Fowler NH et al. Proc ASH 2011;Abstract 99.

Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative.

How I treat refractory CLL

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL by Christian H. Geisler, Mars.

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study by Daniel J. DeAngelo, Wendy.

What is the best frontline regimen for CLL patients

Grövdal M et al. Blood 2008;112:Abstract 223.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p by James I. Barnes, Vasu Divi,

Assessing New Paradigms in CLL: MRD Negativity

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

LBA-4 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Dr Parag Jasani Consultant Haematologist UCLH

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.

Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson

Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration Julio.

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matthew J. Matasar, Myron S. Czuczman,

by Wendy Lim, Sara K. Vesely, and James N. George

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study by Guillermo Garcia-Manero, Yasmin.

Mary Eapen Biology of Blood and Marrow Transplantation

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG.

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term.

Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11.

by Monika Brüggemann, and Michaela Kotrova

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia by Susan M. O'Brien, Nicole Lamanna, Thomas.

Optimizing therapy for nodal marginal zone lymphoma

Presentation transcript:

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia by Pau Abrisqueta, Neus Villamor, María José Terol, Eva González-Barca, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A. García-Marco, Yolanda González, Felix Carbonell, Secundino Ferrer, Encarna Monzó, Isidro Jarque, Ana Muntañola, Mireia Constants, Lourdes Escoda, Xavier Calvo, Sabela Bobillo, José Bruno Montoro, Emili Montserrat, and Francesc Bosch Blood Volume 122(24):3951-3959 December 5, 2013 ©2013 by American Society of Hematology

Consort diagram. Consort diagram. Pau Abrisqueta et al. Blood 2013;122:3951-3959 ©2013 by American Society of Hematology

OS and PFS in the R-FCM trial. OS and PFS in the R-FCM trial. (A) OS and PFS in the whole series. (B) OS and PFS in patients entering the rituximab maintenance-study phase. (C) PFS in patients grouped by MRD levels assessed in PB after induction evaluation. (D) PFS according to MRD levels in BM after induction evaluation. (E) PFS combining the degree of response and the MRD status in PB. Pau Abrisqueta et al. Blood 2013;122:3951-3959 ©2013 by American Society of Hematology

Infectious episodes observed in the R-FCM trial during the maintenance phase. Infectious episodes observed in the R-FCM trial during the maintenance phase. (A) Percentage of grade 3 to 4 infectious episodes. (B) Grade 3 to 4 neutropenia episodes by cycle of treatment. Pau Abrisqueta et al. Blood 2013;122:3951-3959 ©2013 by American Society of Hematology

Comparison of the R-FCM with the previous FCM trial Comparison of the R-FCM with the previous FCM trial.34 (A) Probability of conversion from MRD-negative to MRD-positive in the R-FCM + R and FCM cohorts. Comparison of the R-FCM with the previous FCM trial.34 (A) Probability of conversion from MRD-negative to MRD-positive in the R-FCM + R and FCM cohorts. (B) TNT in patients who achieved a CR MRD-negative after initial treatment with R-FCM or FCM. (C) TNT in patients who achieved a CR MRD-positive after R-FCM or FCM. (D) TNT in patients who achieved a PR after R-FCM or FCM. (E) MRD kinetics of 11 representative patients of the R-FCM + R cohort. Dotted line box represents period under rituximab maintenance. (F) MRD kinetics of 11 representative patients of the FCM cohort. Pau Abrisqueta et al. Blood 2013;122:3951-3959 ©2013 by American Society of Hematology